{
    "paper_id": "PMC7244432",
    "metadata": {
        "title": "A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2",
        "authors": [
            {
                "first": "Swaroop",
                "middle": [],
                "last": "Revannasiddaiah",
                "suffix": "",
                "email": "swarooptheone@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Santhosh",
                "middle": [],
                "last": "Kumar Devadas",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Rasmi",
                "middle": [],
                "last": "Palassery",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Nirdosh",
                "middle": [],
                "last": "Kumar Pant",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Vinayak",
                "middle": [],
                "last": "V Maka",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "A well-coordinated immune response could be important for effective viral clearance in the early phases of the SARS-CoV-2 infection. However, a dysregulated, exuberant immune response in the later phases of the SARS-CoV-2 infection could lead to hyper-inflammatory acute lung injury and ARDS. During the previous SARS-CoV-1 epidemic, immunopathological changes were documented to be involved in the genesis and progression of ARDS.[1]\n",
            "cite_spans": [
                {
                    "start": 431,
                    "end": 434,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "Generally, after pulmonary infection, alveolar macrophages secrete IL-6, IL-12, TNF-alpha, and interferons. Then, as a response, the tissue resident cytotoxic T cells, Th1 cells and Th17 cells secrete further cytokines in increased quantity and diversity. These increased levels of cytokines not only increase the cytotoxic effects of T cells, but also act as a chemoattractant towards circulating monocytes and neutrophils.[3]\n",
            "cite_spans": [
                {
                    "start": 424,
                    "end": 427,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "The development of ARDS in response to infectious agents is rather non-specific, though the severity could vary with the specific circumstance. Experiments with mice using Influenza-A viruses demonstrated that very high viral doses induced extensive neutrophil extracellular traps (NETs). These traps are a mechanism to trap and immobilize pathogens. It is plausible that high viral burden could hence lead to more extensive \u2018NETosis\u2019, thus leading to collateral damage and ultimately impairing gas exchange at the alveoli.[4] Given the high replicative potential of SARS-CoV-2, it is plausible that very high viral burden in the lung leads to a large inflammatory response, which could be fatal.",
            "cite_spans": [
                {
                    "start": 523,
                    "end": 526,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "There ideally exists a balance between the \u2018pro-inflammatory\u2019 and the \u2018anti-inflammatory\u2019. Cells such as the Th1, Th17 and M1-polarized macrophages are pro-inflammatory. At the opposite end of the spectrum, cells such as the regulatory T cells (Treg) and the M2-polarized macrophages are anti-inflammatory and regenerative. In conditions such as ARDS, it can be said that \u2018the balance has shifted overtly in favour of the pro-inflammatory\u2019.[3], [5] Studies with patients infected with the SARS-CoV-1 had indeed demonstrated increased pro-inflammatory cytokine levels among those who developed ARDS.[6], [7]\n",
            "cite_spans": [
                {
                    "start": 440,
                    "end": 443,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 445,
                    "end": 448,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 598,
                    "end": 601,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 603,
                    "end": 606,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "Of the various T-helper (Th) subsets, the Tregs are special in that they are vital for maintaining self-tolerance. Tregs express CD4+CD25+FoxP3 and produce the anti-inflammatory cytokine namely IL-10. Evidence suggests that Tregs have an ability to downregulate TNF-alpha, IL-2 and IL-8. Thus, manipulation of T cell populations to enhance proportion of Tregs may possibly be a worthwhile exercise in the mitigation of acute lung injury.[8]\n",
            "cite_spans": [
                {
                    "start": 437,
                    "end": 440,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "Available evidence suggests that an increased Th17:Treg ratio is known to be pro-inflammatory and conducive to the development of ARDS.[8] In fact, the Th17/Treg ratio has been seen as a prognostic marker for ARDS in terms of mortality prediction.[9]\n",
            "cite_spans": [
                {
                    "start": 135,
                    "end": 138,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 247,
                    "end": 250,
                    "mention": "[9]",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "Worthy of mention, the occasional manifestation of hemophagocytosis in patients infected with SARS-CoV-2 serves as a testament to excessive macrophage activation, which can in turn be attributed to excessive proliferation and activation of T-Cells.[10]\n",
            "cite_spans": [
                {
                    "start": 248,
                    "end": 252,
                    "mention": "[10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Immunological Basis of ARDS:",
            "ref_spans": []
        },
        {
            "text": "It is encouraging that IL-6 antagonists such as tocilizumab are being rightly investigated in SARS-CoV-2 related ARDS.[11] It is furthermore encouraging that groups are contemplating TNF-alpha antagonists such as infliximab and etanercept in the setting.[12]\n",
            "cite_spans": [
                {
                    "start": 118,
                    "end": 122,
                    "mention": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 254,
                    "end": 258,
                    "mention": "[12]",
                    "ref_id": "BIBREF11"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Drugs such as tocilizumab, and other targeted monoclonal antibodies could do well in targeting the particular cytokine which they are designed to. However, ARDS is a hyperinflammatory condition involving multiple pro-inflammatory cytokines, and thus we postulate that targeting one single cytokine could be a weak approach. The use of cyclophosphamide would strike at the root of the hyper-inflammatory condition by rapidly depleting effector T cells.",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Cyclophosphamide has been more renowned for its role as an alkylating agent in various cancer specific chemotherapeutic regimens. It has also been well documented to have other roles as an immunomodulator in various auto-immune disorders with a reasonable toxicity profile.[13]\n",
            "cite_spans": [
                {
                    "start": 273,
                    "end": 277,
                    "mention": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Cyclophoshamide had revolutionized the scene of haplo-identical allogenic stem cell transplants (HaploSCT). HaploSCT essentially involves transplants from a donor who is \u2018not fully matched\u2019 to the recipient. The use of post-transplant cyclophosphamide (PTCY) has led to a dramatic reduction in likelihood of graft versus host disease (GVHD) and graft rejections. This is because PTCY works to eliminate rapidly proliferating alloreactive T-cells (in both directions) while preserving the slowly dividing regulatory-T cells (T-regs) and memory T cells. This not only leads to lesser likelihood of GVHD and graft rejection, but also leads to better immune tolerance and immune reconstitution.[14], [15], [16]\n",
            "cite_spans": [
                {
                    "start": 690,
                    "end": 694,
                    "mention": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 696,
                    "end": 700,
                    "mention": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 702,
                    "end": 706,
                    "mention": "[16]",
                    "ref_id": "BIBREF15"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Cyclophosphamide has a rich history of being used as an effective rescue therapy when other drugs failed in severe rheumatological disorders, which too have an immunological pathogenesis. This use has somewhat declined in the previous decade owing to the development of targeted monoclonal antibodies against specific cytokines.[13]\n",
            "cite_spans": [
                {
                    "start": 328,
                    "end": 332,
                    "mention": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "If being considered as a preventive/mitigative strategy against ARDS in SARS-CoV-2, we need to ponder upon the ideal dose and the ideal timing of cyclophosphamide delivery.",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "The dose of cyclophosphamide used in various conditions is vastly different. Certain protocols for PTCY use doses as high as 50 mg/kg. However, we could possibly utilize lower doses given that we are aiming at a reduction of cytotoxic T cells rather than a total elimination. As an example, when cyclophosphamide is utilized as an immunomodulator in multiple sclerosis, the applied dose is many magnitudes less.[17] So, a 10-20 mg/kg dose of cyclophosphamide could be able to demonstrate proof of concept.",
            "cite_spans": [
                {
                    "start": 411,
                    "end": 415,
                    "mention": "[17]",
                    "ref_id": "BIBREF16"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Regarding the ideal timing of cyclophosphamide, it would be advisable to wait to start till when ARDS is deemed inevitable. That would be at the onset of acute lung injury, with the patient yet to proceed to fully established ARDS.",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Regarding the questionable safety of using an alkylating agent in the setting, we justify the same that ARDS is otherwise potentially lethal.[13] Furthermore, a one-off dose would be employed rather than multiple doses as would be in the case with malignancies. The use of broad spectrum antibiotics akin to the stem-cell transplant setting would be advisable so as to prevent bacterial and fungal opportunistic infections.",
            "cite_spans": [
                {
                    "start": 141,
                    "end": 145,
                    "mention": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "An interesting case report describes a young patient who was treated with a regimen including cyclophosphamide for glomerulonephritis. The patient later was found to have ground glass opacities on computed tomography imaging and subsequently tested positive for SARS-CoV-2. It could be possible that the use of cyclophosphamide could have prevented the particular patient from manifesting severe pulmonary symptoms [18].",
            "cite_spans": [
                {
                    "start": 415,
                    "end": 419,
                    "mention": "[18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "If at all a strategy using cyclophosphamide is found effective in mitigating/preventing SARS-CoV-2 associated ARDS, it is plausible that it could be put into immediate global use. Unlike monoclonal antibodies the cost of cyclophosphamide is very much affordable. In addition, cyclophosphamide production can quickly be ramped up using existing pharmaceutical infrastructure, while manufacturing monoclonal antibodies on a large scale in a short time span could be problematic.",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Author Statements",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "All authors have equally contributed to the concept and the preparation of the manuscript",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "Conflict of interest: All authors declare that there are no conflicts of interests",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        },
        {
            "text": "No funding was sought or received for this manuscript.",
            "cite_spans": [],
            "section": "Immune modulation as an option against ARDS:",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology",
            "authors": [
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Channappanavar",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Semin Immunopathol.",
            "volume": "39",
            "issn": "",
            "pages": "529-539",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "in China",
            "authors": [
                {
                    "first": "W.J.",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z.Y.",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Clinical",
                    "middle": [],
                    "last": "Characteristics",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "of Coronavirus Disease",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "N Engl J Med",
            "volume": "2020",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF2": {
            "title": "Insights into the immuno-pathogenesis of acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "J.J.M.",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "J.Y.",
                    "middle": [],
                    "last": "Leong",
                    "suffix": ""
                },
                {
                    "first": "J.H.",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Ann Transl Med.",
            "volume": "7",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis",
            "authors": [
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Narasaraju",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "R.P.",
                    "middle": [],
                    "last": "Samy",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Am J Pathol.",
            "volume": "179",
            "issn": "",
            "pages": "199-210",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "T cell-mediated immune response to respiratory coronaviruses",
            "authors": [
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Channappanavar",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Immunol Res.",
            "volume": "59",
            "issn": "",
            "pages": "118-128",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome",
            "authors": [
                {
                    "first": "C.K.",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "C.W.",
                    "middle": [],
                    "last": "Lam",
                    "suffix": ""
                },
                {
                    "first": "A.K.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Clin Exp Immunol.",
            "volume": "136",
            "issn": "",
            "pages": "95-103",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Immunopathogenesis of coronavirus infections: implications for SARS",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                },
                {
                    "first": "A.A.",
                    "middle": [],
                    "last": "Dandekar",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nat Rev Immunol.",
            "volume": "5",
            "issn": "",
            "pages": "917-927",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Front Immunol.",
            "volume": "9",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "Z.X.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "M.S.",
                    "middle": [],
                    "last": "Ji",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Crit Care",
            "volume": "19",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients",
            "authors": [
                {
                    "first": "J.T.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Sheng",
                    "suffix": ""
                },
                {
                    "first": "C.T.",
                    "middle": [],
                    "last": "Fang",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Emerg Infect Dis.",
            "volume": "10",
            "issn": "",
            "pages": "818-824",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "COVID-19: consider cytokine storm syndromes and immunosuppression",
            "authors": [
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Mehta",
                    "suffix": ""
                },
                {
                    "first": "D.F.",
                    "middle": [],
                    "last": "McAuley",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Brown",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet.",
            "volume": "395",
            "issn": "",
            "pages": "1033-1034",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "",
            "authors": [],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "395",
            "issn": "10234",
            "pages": "1407-1409",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30858-8"
                ]
            }
        },
        "BIBREF12": {
            "title": "Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Dan",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Fischer",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Adler",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Swiss Med Wkly.",
            "volume": "23",
            "issn": "144",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application",
            "authors": [
                {
                    "first": "R.",
                    "middle": [],
                    "last": "El Fakih",
                    "suffix": ""
                },
                {
                    "first": "S.K.",
                    "middle": [],
                    "last": "Hashmi",
                    "suffix": ""
                },
                {
                    "first": "S.O.",
                    "middle": [],
                    "last": "Ciurea",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Bone Marrow Transplant.",
            "volume": "55",
            "issn": "",
            "pages": "40-47",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Cyclophosphamide-induced immunological tolerance: an overview",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Mayumi",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Umesue",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Nomoto",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Immunobiology.",
            "volume": "195",
            "issn": "",
            "pages": "129-139",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Luznik",
                    "suffix": ""
                },
                {
                    "first": "P.V.",
                    "middle": [],
                    "last": "O'Donnell",
                    "suffix": ""
                },
                {
                    "first": "E.J.",
                    "middle": [],
                    "last": "Fuchs",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Semin Oncol.",
            "volume": "39",
            "issn": "",
            "pages": "683-693",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Brochet",
                    "suffix": ""
                },
                {
                    "first": "M.S.",
                    "middle": [],
                    "last": "Deloire",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Perez",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "PLoS One.",
            "volume": "12",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Moeinzadeh",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Dezfouli",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Naimi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Iran J Kidney Dis.",
            "volume": "14",
            "issn": "",
            "pages": "239-242",
            "other_ids": {
                "DOI": []
            }
        }
    }
}